This page contains a Flash digital edition of a book.
laboratory informatics


Analysis issues And herein lies the data-analysis problem, Leven points out. Laboratory informatics and compound management systems applied to traditional ‘one well, one compound’ screening workflows weren’t immediately capable of handling the selection, dispensing, screening, and data management/analysis of two different compounds in a single well in a test plate. ‘It’s an issue that has now been addressed


at the compound management level by at least one of the major vendors of compound storage and management soſtware, and Genedata has been working with clients to provide a solution at the informatics level by introducing new capabilities within our Genedata Screener platform.’ Te latest developments in this area were announced at the end of 2013 when Genedata reported on the successful completion of its collaboration with AstraZeneca, which focused on the development of a Genedata Screener soſtware extension that can automate and standardise the analysis of combination compound screening workflows. ‘Since then, we’ve been inundated with interest from pharma companies looking for


the informatics capabilities that will allow them to unlock this area of drug discovery’, Leven says. ‘And as with any analytical workflow in


the pharma industry, the ultimate aim is to be able to increase throughput, which for combination screening requires informatics systems that can manage and analyse a squared helping of data per experiment. ‘Coming from the issue of the numbers of wells screened, it’s not so much a case of HTS goes combination, as combination goes HTS.’


Hang on to your data High-throughput experimentation in any field of drug discovery or development inevitably results in the generation of massive amounts of data. A decade or so ago, pharmaceutical


companies would erase data from discovery- stage compounds that didn’t have any immediate developmental future, but over recent years there has been a move towards keeping all the data, explains Terry Smallmon, director of life science sales at LabVantage Solutions. ‘Trowing 90 per cent of your data away doesn’t make sense in an era when new


discoveries about disease pathways and biological processes are leading to new approaches to therapy,’ he suggests. A compound that doesn’t exhibit the


desired activity against one target may impact another target and, as biological discoveries emerge, display potential utility in a completely different therapeutic field.


BUSINESS


INTELLIGENCE AND DATA VISUALISATION TOOLS ARE PROVIDING NEW INSIGHTS FROM MINED DATA


Tat therapeutic field may not be within the IP holder’s direct area of expertise, but it may open up potential avenues for out-licensing deals or co-development partnerships. Business intelligence and data visualisation tools are providing new insights and oſten valuable information from mined data, thus justifying the need for pharmaceutical companies to hang on to every piece of information they generate.’


Make the Connection…From Data to Intelligence


Unify Analytical and Chemical Data for Greater Efficiency and Productivity


Generate Knowledge from Information for Faster Decision-Making


Create Intelligence for Collaborative Science


Integrate with Existing LIMS, ELNs, and Other Informatics Systems


ACD/Spectrus Platform Making Unified Laboratory Intelligence a Reality Meet ACD/Labs


Analytica 2014 1st


-4th www.acdlabs.com/spectrus April, 2014 Hall A2, Booth 137C


Paperless Lab Academy 13-14th


May, 2014


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40